RxDoctor Payments Data

Jill Jarvis, PA

Medical · Louisville, KYNPI 1750533717

Payments from drug & device makers

$553in general payments, 2019–2025

Across 26 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$249
  • AbbVie$152
  • Lilly USA, LLC$64
  • Boehringer Ingelheim$30
  • Vanda Pharmaceuticals Inc.$24
  • Dexcom, Inc.$19
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$553100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$553 in reported general payments places this provider in the 40th percentile of 222 medical providers in Kentucky.

See all medical providers in Kentucky

Medicare billing

Part B allowed, 2024
$25,155
Medicare patients
70
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$69,611
EliquisApixaban46$42,569
MounjaroTirzepatide20$29,187
JanuviaSitagliptin Phosphate23$25,011
JardianceEmpagliflozin13$21,259
TrulicityDulaglutide11$15,884
LinzessLinaclotide11$13,178
Breo ElliptaFluticasone/Vilanterol11$10,170
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$9,163
Varenicline Tartrate19$5,631
SymbicortBudesonide/Formoterol Fumarate11$5,517
Albuterol Sulfate HfaAlbuterol Sulfate178$5,222
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$1,872
Diclofenac Sodium40$1,501
Potassium Chloride40$1,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$249$69,61146 claims
Lilly USA, LLCMounjaro, Trulicity$64$45,07231 claims
Boehringer IngelheimJardiance$30$21,25913 claims
AbbVieLinzess, Synthroid$152$14,17324 claims
AstraZenecaSymbicort$16$5,51711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 222 medical providers in Kentucky.

Other medical in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →